BioNTech SE

BNTXintermediary

BioNTech is a German biotechnology company that co-developed the first authorized mRNA COVID-19 vaccine with Pfizer. It is now leveraging its mRNA platform for individualized cancer vaccines, infectious disease programs, and cell therapies.

共有:

⇄ Compare

製品と売上

製品別売上シェア

売上内訳 ($4.8B)

静的データ（リアルタイム財務ロード中…）

COVID-19 Vaccine Revenue (68%)

Collaboration Revenue (Pfizer) (18%)

R&D Grants & Other (14%)

セグメント構成と主要顧客

製品詳細

Comirnaty (COVID-19 Vaccine)55%

mRNA-based COVID-19 vaccine developed with Pfizer

Oncology mRNA (BNT111, BNT122)15%

Individualized mRNA cancer vaccines targeting solid tumors

Infectious Disease Pipeline10%

mRNA vaccines for influenza, shingles, and malaria

サプライチェーン関係

パートナー

Pfizer Inc.

Comirnaty COVID vaccine co-development

影響: Critical — Pfizer is primary commercialization partner

競合他社

Moderna, Inc.

mRNA vaccines and oncology

影響: Primary mRNA competitor

Regeneron Pharmaceuticals

Cancer immunotherapy

影響: Competing in oncology

マクロ・市場概況

제약 / 바이오セクターニュース

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

次の主要イベント

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI分析

BioNTech SEのAIサプライチェーン分析を受けるには「AI分析を取得」をクリックしてください。

企業情報

本社所在地

Mainz, Germany

設立

2008

従業員数

6,000+

ウェブサイト

biontech.com

セクター概況 — 제약 / 바이오

セクターニュース